PMID: 12034136May 30, 2002

The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?

Neuroscience and Biobehavioral Reviews
Peter TurroneJ N Nobrega


Tardive dyskinesia (TD) is a late side effect of long-term antipsychotic use in humans, and the vacuous chewing movement (VCM) model has been used routinely to study this movement disorder in rats. Recent receptor occupancy studies in humans and rats have found that antipsychotics given in doses which lead to moderate levels of D(2) receptor blockade can achieve optimal clinical response while minimizing the emergence of acute motor side effects. This suggests that clinicians may have been using inappropriately high doses of antipsychotics. A review of the existing VCM literature indicates that most animal studies have similarly employed antipsychotic doses that are high, i.e. doses that lead to near complete D(2) receptor saturation. To verify whether the incidence or severity of VCMs would decrease with lower antipsychotic doses, we conducted initial experiments with different doses of haloperidol (HAL) given either as repeated daily injections or as depot injections over the course of several weeks. Our results demonstrate that (1) the incidence of VCMs is significantly related to HAL dose, and (2) significant levels of VCMs only emerge when haloperidol is continually present. These findings are consistent with the possibili...Continue Reading


Aug 1, 1979·Danish Medical Bulletin·J Gerlach
Feb 18, 1992·European Journal of Pharmacology·M DianaG L Gessa
Feb 25, 1992·European Journal of Pharmacology·H KanedaC A Tamminga
Nov 13, 1990·European Journal of Pharmacology·B GlenthøjT G Bolwig
Jan 1, 1989·Psychopharmacology·J N NobregaH T Barros
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·L M Gunne, P Johansson
Apr 1, 1989·Pharmacology, Biochemistry, and Behavior·D WeinsteinG Ellison
Jan 1, 1986·Psychopharmacology·N M RupniakC D Marsden
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·L M GunneP Johansson
Jan 1, 1987·Psychopharmacology·G EllisonJ Kinney
Jan 1, 1988·Schizophrenia Bulletin·N C AndreasenG Sedvall
Aug 1, 1988·Journal of Clinical Psychopharmacology·D V JesteR J Wyatt
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·R Yassa, V Nair
Jan 1, 1972·Journal of Neural Transmission·H L Klawans, R Rubovits
Nov 1, 1972·Archives of Neurology·G E Crane
Oct 1, 1982·Journal of Clinical Psychopharmacology·L M Gunne, J H Growdon
Apr 1, 1995·Neuropharmacology·A J Stoessl
Dec 27, 1994·European Journal of Pharmacology·N Y Huang, R M Kostrzewa
Feb 1, 1995·Pharmacology, Biochemistry, and Behavior·N SeilerS Gobaille
Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J StoesslH Frydryszak
Jan 1, 1993·Acta Psychiatrica Scandinavica·G MuscettolaP Bollini
Jan 1, 1993·Schizophrenia Bulletin·D V Jeste, M P Caligiuri
Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R E See
Jul 1, 1996·Pharmacology, Biochemistry, and Behavior·A J Stoessl
Jul 1, 1996·Physiology & Behavior·R E SteinpreisA Harrington
Feb 1, 1996·Pharmacology, Biochemistry, and Behavior·M F EganT M Hyde
Jul 1, 1997·Behavioural Brain Research·R E SteinpreisJ J Panos
Jan 27, 1998·Pharmacopsychiatry·E M Haberfellner
Mar 10, 1998·The Journal of Clinical Psychiatry·B M Saran
Apr 30, 1998·Pharmacopsychiatry·P FischerB Küfferle
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·H TakeuchiS Miura
Oct 21, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·X M GaoC A Tamminga
Nov 3, 1998·Biological Psychiatry·M H ChakosC A Tamminga
Jan 1, 1999·Progress in Neurobiology·J D SalamoneA Nawab
Mar 11, 1999·Neuropsychobiology·U SchmittC Hiemke
Jun 1, 1999·Journal of Clinical Psychopharmacology·M Campbell
Nov 5, 1999·Pharmacology, Biochemistry, and Behavior·O A AndreassenH A Jørgensen
Apr 26, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S KapurG Remington
Nov 10, 2000·Pharmacopsychiatry·M Marsálek
Apr 27, 2001·Toxicology Letters·P HartvigB Långström
Jun 16, 2001·European Journal of Pharmacology·P S Naidu, S K Kulkarni
Jun 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·S Ipekçi, S Birsöz
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·P SakkasG N Christodoulou


Mar 7, 2006·Psychopharmacology·Spiridon KonitsiotisAngelos Evangelou
Oct 2, 2003·European Journal of Pharmacology·Robert E McCullumsmithJames H Meador-Woodruff
Aug 2, 2005·Journal of Neuroscience Methods·Sonja B SchleimerJasmine M Henderson
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marilise E BurgerJoão B T Rocha
Nov 17, 2010·The Pharmacogenomics Journal·James J CrowleyPatrick F Sullivan
Feb 7, 2007·Current Opinion in Psychiatry·G Remington
Dec 7, 2011·The Journal of Pharmacology and Experimental Therapeutics·Tanuja BordiaMaryka Quik
Mar 13, 2012·Behavioral and Brain Functions : BBF·Pierre J BlanchetDaniel Lévesque
Dec 31, 2011·Mammalian Genome : Official Journal of the International Mammalian Genome Society·James J CrowleyPatrick F Sullivan
Apr 5, 2013·The European Journal of Neuroscience·Souha MahmoudiDaniel Lévesque
Jun 30, 2004·Neuropharmacology·V C AbílioR Frussa-Filho
Apr 9, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Joseph L McClayEdwin J van den Oord
Aug 16, 2011·Pharmacology, Biochemistry, and Behavior·G RemingtonSridhar Natesan
Feb 15, 2014·The International Journal of Neuropsychopharmacology·Anne L WheelerJ N Nobrega
Oct 19, 2016·Neurochemical Research·Tafheem MalikDarakhshan Jabeen Haleem
Jul 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter TurroneJ N Nobrega
Sep 14, 2013·The Journal of Pharmacology and Experimental Therapeutics·Roger D PorsoltDavid Virley
Jul 23, 2020·G3 : Genes - Genomes - Genetics·Paola Giusti-RodríguezFei Zou
Jan 5, 2017·Case Reports in Dentistry·S LumettiE Manfredi
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
May 14, 2017·Scientific Reports·Paulo A de OliveiraFrancisco Ciruela
Aug 14, 2019·Progress in Neurobiology·Bastien RibotPierre Burbaud
Jul 14, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Meaghan CreedJ N Nobrega

Related Concepts

Dyskinesia, Medication-Induced
Hyperkinesia, Generalized
Antipsychotic Effect
Dopamine D2 Receptor
Dopamine Antagonists

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here